QRxPharma meets with FDA about MoxDuo IR knockback
20 August, 2012 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) executives left a pivotal meeting with the US FDA hopeful of being able to avoid prolonging the MoxDuo IR approvals process with another clinical trial.
Manufacturing Taskforce largely overlooks biotechnology
17 August, 2012 by Tim DeanThe Prime Minister’s Manufacturing Taskforce report from non-government members, released yesterday, has focused largely on traditional manufacturing with little attention given to the biotechnology, pharmaceutical and medical device manufacturing sectors.
AusBiotech national office on the move…
16 August, 2012 by AusBiotechThe national office of AusBiotech will move this weekend from its current location in Malvern to Level 4, 627 Chapel Street, South Yarra Victoria.
Opinion: Scrapping the R&D tax incentive is hardly a smart idea for economic policy
16 August, 2012 by Staff WritersThe Business Tax Working Group discussion paper’s suggestion to reduce the R&D tax incentive reveals a clear-cut attitude to policy aimed at Australia’s economic development: “It’s all about the tax take.”
Government quells concerns about R&D Tax Incentive
16 August, 2012 by Tim DeanIndustry Minister Greg Combet has moved to quell concerns that the fledgling R&D Tax Incentive could be trimmed in order to help fund a cut to the corporate tax rate, as raised by the government’s Business Tax Working Group discussion paper.
Cancer Therapeutics licences breast cancer programs
16 August, 2012 by Dylan Bushell-EmblingTwo FAK inhibitors developed by Australia's Cancer Therapeutics CRC – which are showing promise in treating triple-negative breast cancers and other solid tumours – are on their way to commercialisation.
Immuron testing anti-influenza drug against swine flu
15 August, 2012 by Dylan Bushell-EmblingImmuron (ASX:IMC) has started a new round of animal studies for its IMM-255 OTC influenza treatment candidate, this time in the swine flu strain.
AtCor wins $1.1m deal for SphygmoCor XCEL
15 August, 2012 by Dylan Bushell-EmblingAtCor Medical (ASX:ACG) has secured a $1.1 million contract to provide its SphygmoCor XCEL cardiac monitoring system to an international pharmaceutical company.
Bioniche to sell equine probiotic
14 August, 2012 by Dylan Bushell-EmblingBioniche (ASX:BNC) is continuing to build up its animal health product portfolio, signing a deal to allow it to distribute an equine probiotic.
AusBiotech comments on the National Research Investment Plan discussion paper
14 August, 2012 by AusBiotechAusBiotech has made a formal response to the Federal Government’s discussion paper on the National Research Investment Plan (NRIP) giving the Australian Research Committee (ARCom) a biotechnology industry perspective.
Nexvet signs first deal for veterinary drug
10 August, 2012 by Dylan Bushell-EmblingVeterinary drug developer Nexvet has signed the first licensing deal covering a biologic drug adapted for animal use using its PETization process.
Advanced Leadership Program scholarships for AusBiotech members
09 August, 2012 by AusBiotechWoman & Leadership Australia has announced two $11,000 scholarships to be awarded to AusBiotech members to assist their participation in the Advanced Leadership Program.
Bioniche E. coli vaccine cleared for import into UK
09 August, 2012 by Dylan Bushell-EmblingA UK department has granted veterinarians special dispensation to import a cattle vaccine against E. coli O157 developed by Bioniche (ASX:BNC).
GeneWorks develops DNA barcoding tech
08 August, 2012 by Dylan Bushell-EmblingSouth Australia's GeneWorks has developed a DNA barcoding security technology compatible with existing forensic laboratory instruments.
GTG gets CE Mark for breast cancer test
08 August, 2012 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has won European CE Mark approval for BREVAGen, its DNA test for increased breast cancer risk.
